Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Mesoblast Limited ( (AU:MSB) ) has shared an announcement.
Mesoblast Limited announced the appointment of Lyn Cobley as a new director, effective April 29, 2025. Cobley holds 33,000 ordinary shares through Synergy Finance Pty Ltd as trustee for Cobley Superfund. This appointment may influence the company’s strategic direction and stakeholder confidence, given Cobley’s experience and interests in the company.
More about Mesoblast Limited
Mesoblast Limited operates in the biotechnology industry, focusing on developing cellular medicines. The company specializes in regenerative medicine, aiming to treat a range of diseases with its proprietary technology platform.
YTD Price Performance: -31.82%
Average Trading Volume: 400,962
Technical Sentiment Signal: Sell
Current Market Cap: $1.46B
For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.